Markets:

Overview

News

Currencies

International

Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

18.31 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Feb 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2

...

28 29 30 31 32 33 34 35 Next >

Meta Platforms To Rally 27%? Here Are 10 Other Analyst Forecasts For Thursday ↗

March 09, 2023

Wells Fargo cut the price target for SVB Financial Group (NASDAQ: SIVB) from $350 to $300. Wells Fargo analyst Steven Shaw maintained an Overweight rating. SVB Financial shares fell 29.1% to $190.02 in...

Via Benzinga

2 Biotech Stocks You Can Buy and Hold for the Next Decade ↗

March 09, 2023

Regeneron and Sarepta Therapeutics have been on fire so far this year.

Via The Motley Fool

The Latest Analyst Ratings for Sarepta Therapeutics ↗

March 03, 2023

Via Benzinga

Stock Market Rally Rebounds Despite Rising Yields; Salesforce, Tesla In Focus: Weekly Review ↗

March 03, 2023

Many leaders flashed buy signals as the indexes rebounded from support.

Via Investor's Business Daily

Novavax Stock Down On Concern Over Whether The Company Can Continue ↗

February 28, 2023

Novavax warns that it may not be able to continue as a company.

Via Talk Markets

Expert Ratings for Sarepta Therapeutics ↗

February 15, 2023

Via Benzinga

9 Analysts Have This to Say About Sarepta Therapeutics ↗

January 20, 2023

Via Benzinga

Why Sarepta Therapeutics' Shares Rose 23.4% This Week ↗

March 02, 2023

The company's latest Duchenne muscular dystrophy gene therapy may have an accelerated approval.

Via The Motley Fool

3 Best Growth Stocks to Buy In March ↗

March 02, 2023

These three red-hot growth stocks have more room to run.

Via The Motley Fool

Why Sarepta Therapeutics Stock Is Booming Today ↗

March 01, 2023

Sarepta Therapeutics (NASDAQ: SRPT) shares are trading higher this Wednesday after the company reported better-than-expected fourth-quarter results.

Via Benzinga

Why This Sarepta Therapeutics Is Turning Bullish ↗

March 01, 2023

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) jumped in early trading on Wednesday, after the company reported an earnings beat for its fourth quarter.

Via Benzinga

3D Systems, CarGurus, Sarepta Therapeutics And Other Big Stocks Moving Higher On Wednesday ↗

March 01, 2023

U.S. stocks traded lower, with the Dow Jones dropping around 80 points on Wednesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Why Novavax Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

March 01, 2023

Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) shares jumped 171.5% to $84.67 after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia.

Via Benzinga

Sarepta Rockets And Breaks Out As FDA Smooths The Path For Its Gene Therapy ↗

March 01, 2023

The FDA will not hold an advisory committee meeting for the company's gene therapy.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023 ↗

March 01, 2023

Via Benzinga

Why Is Sarepta Therapeutics (SRPT) Stock Up 21% Today? ↗

March 01, 2023

Sarepta Therapeutics (SRPT) stock is heading higher on Wednesday following the release of its latest earnings report and an upgrade.

Via InvestorPlace

Investors Just Hit the Jackpot on These 2 Nasdaq Biotech Stocks ↗

March 01, 2023

Markets are trying to rise, and these companies are helping out.

Via The Motley Fool

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

March 01, 2023

Via Benzinga

Sarepta Therapeutics To Rally Over 53%? Here Are 10 Other Analyst Forecasts For Wednesday ↗

March 01, 2023

Keybanc raised the price target for Ambarella, Inc. (NASDAQ: AMBA) from $95 to $105. Keybanc analyst John Vinh maintained an Overweight rating. Ambarella shares fell 7.1% to $87.61 in pre-market...

Via Benzinga

Why Reata Pharmaceuticals Shares Are Trading Higher By 140%; Here Are 20 Stocks Moving Premarket ↗

March 01, 2023

Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) rose 140.8% to $75.06 in pre-market trading after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

March 01, 2023

It's time to start the day with another breakdown of the biggest pre-market stock movers traders need to know about on Wednesday!

Via InvestorPlace

Sarepta Therapeutics (SRPT) Q4 2022 Earnings Call Transcript ↗

February 28, 2023

SRPT earnings call for the period ending December 31, 2022.

Via The Motley Fool

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 28, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

February 28, 2023

Via Benzinga

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments

February 28, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Announces Call for Applications for the 6th Annual Route 79, The Duchenne Scholarship Program

February 28, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2022 Financial Results

February 21, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Announces Initiation of VOYAGENE, a Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4

February 17, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

Earnings Scheduled For February 28, 2023 ↗

February 28, 2023

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter.

Via Benzinga

3 Gene Editing Stocks With the Best Long-Term Potential ↗

January 25, 2023

These gene editing stocks are likely to deliver massive gains ahead in the fast-evolving biotech space

Via InvestorPlace

< Previous 1 2

...

28 29 30 31 32 33 34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

All News about Sarepta Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today